TrialNet is a collaborative effort to prevent type 1 diabetes.
TrialNet is an international consortium of centers dedicated to the study, prevention, and early detection and treatment of type 1 diabetes. Researchers are part of a larger network called Type 1 Diabetes TrialNet. With 21 clinical centers in the United States, Canada, Europe, and Australia, we are conducting studies to:
- Test family members of people with type 1 diabetes to determine their risk to develop T1D as well.
- Learn more about the common risk factors among people who develop type 1 diabetes.
- Test treatments that could delay or prevent the onset of type 1 diabetes.
- Test treatments that might help people who have been recently diagnosed keep producing their own insulin.
TrialNet at UF
The mission of TrialNet at the University of Florida is to 1) identify family members at risk, and 2) evaluate promising new therapies to prevent, slow or reverse the progression of the disease.
The Pathway to Prevention Study offers a simple blood test that can identify the risk for type 1 diabetes up to 10 years before symptoms actually appear. TrialNet researchers have screened over 170,000 participants, with the hopes of reducing complications and helping countless others at risk for type 1 diabetes.